Somaxon Pharmaceuticals, Inc.

(NASDAQ:SOMX)
  Sep 30, 2008 Jun 30, 2008 Mar 31, 2008 Dec 31, 2007
Operating revenue
Total Revenue — — — —
Operating Revenue — — — —
Adjustments To Revenue — — — —
Cost Of Sales 41 -36 -93 -43
Cost Of Sales With Depreciation — — — —
Gross Operating Profit -41 36 93 43
Operating Expenses
Research And Development Expenses 4,594 5,849 3,176 3,058
Selling General And Administrative Expenses 5,385 4,572 4,248 5,247
Advertising Expenses — — — —
Operating Income Before Depreciation -10,020 -10,385 -7,331 -8,262
Operating Income -9,979 -10,421 -7,424 -8,305
Depreciation -41 36 93 43
Depreciation Unreconciled — — — —
Amortization — — — —
Amortization Of Intangibles — — — —
Operating Income After Depreciation -9,979 -10,421 -7,424 -8,305
Non Operating Expenses
Interest Expense 333 — — —
Pre Tax Income -10,312 -10,395 -7,066 -7,805
Income Taxes — — — —
Minority Interest — — — —
Income Before Income Taxes — — — —
Net Income From Continuing Operations -10,312 -10,395 -7,066 -7,805
Net Income From Discontinued Operations — — — —
Net Income From Total Operations -10,312 -10,395 -7,066 -7,805
Non Recurring Events
Extraordinary Income Losses — — — —
Income From Cummulated Effect Of Accounting Changes — — — —
Income From Tax Loss Carryforward — — — —
Other Gains And Losses — — — —
Total Net Income -10,312 -10,395 -7,066 -7,805
Normalized Income -10,312 -10,395 -7,066 -7,805
NetIncome Available For Common -10,312 -10,395 -7,066 -7,805
Preferred Dividends — — — —
Excise Taxes — — — —